Clinical Development of a Therapeutic Agent for COPD
慢性阻塞性肺病治疗剂的临床开发
基本信息
- 批准号:8912535
- 负责人:
- 金额:$ 100万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-09-29 至 2018-05-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAir PollutionAllergic rhinitisApplications GrantsArchitectureAsthmaBooksBreathingBronchiectasisCanis familiarisCause of DeathCessation of lifeChronicChronic BronchitisClinicalClinical ResearchCoughingCystic FibrosisDataDevelopmentDiagnosisDiseaseDoseDouble-Blind MethodEconomic BurdenEpithelial CellsExertionFundingGasesGrantHealthHoward Temin AwardHumanImpairmentIncidenceIndividualInflammationInflammation MediatorsLeadLungLung diseasesMARCKS geneMarketingMedicalMorbidity - disease rateMucous body substancePathway interactionsPatient CarePatientsPeptidesPharmaceutical PreparationsPharyngeal structurePhasePhysiologicalPlacebosPopulationPreparationPrincipal InvestigatorProteinsProviderPulmonary EmphysemaRattusRespiratory physiologyRodent ModelSafetyShortness of BreathSiteSmall Business Innovation Research GrantSmokerSymptomsTherapeutic AgentsUnited States National Institutes of HealthWheezingWorkWorld Health Organizationaerosolizedairway inflammationairway obstructionbasecohorteffective therapyinhibitor/antagonistmortalitymucus hypersecretionnovelrespiratorysafety studysocialtherapeutic target
项目摘要
DESCRIPTION (provided by applicant): Hypersecretion of mucus into the respiratory airways is a major contributing factor in several lung diseases, including chronic pulmonary disease (COPD), asthma, cystic fibrosis, allergic rhinitis, and bronchiectasis. Despite the obvious medical importance, there presently are no effective therapies to control excess mucus secretion in these diseases, and very few potential therapeutic targets. We discovered that a specific protein called MARCKS is a key molecule in the mucus secretary pathway. Based on this finding BioMarck developed a novel peptide, BIO-11006, which inhibited mucus hypersecretion as well as release of inflammatory mediators in human airway epithelial cells in culture and in various rodent models. BIO-11006, being a dual function inhibitor mucus secretion and inflammation, is an ideal drug to potentially treat various lung diseases including COPD. With funding from SBIR grants, BioMarck continued work on this project and has recently successfully completed, under an active IND, a 21-day proof-of-concept Phase 2A clinical study in 172 COPD patients suffering from chronic bronchitis with its lead compound BIO-11006. This SBIR Phase II Bridge grant application will allow BioMarck to undertake a 90-day Phase 2B multi center, double blind, dose selection clinical study with BIO-11006 with 300 COPD patients suffering from chronic bronchitis. A successful completion of the proposed project will allow BioMarck to select a dose level for the final Phase 3 clinical study. Worldwide the social and economic burden of COPD is enormous. COPD, being the 3th. leading cause of death, accounts for over 5 million deaths worldwide. Although there are more than 25 different drugs currently available in the market, the patients and the care providers are desperate for effective drugs for the treatment of COPD. BIO- 11006, by reducing both excess mucus and airway inflammation, has the potential to be a first in class drug to effectively treat this patien population.
描述(申请人提供):粘液过度分泌到呼吸道是几种肺部疾病的主要致病因素,包括慢性肺部疾病(COPD)、哮喘、囊性纤维化、过敏性鼻炎和支气管扩张。尽管具有明显的医学重要性,但目前还没有有效的治疗方法来控制这些疾病的过度粘液分泌,而且几乎没有潜在的治疗靶点。我们发现,一种名为Marcks的特定蛋白质是粘液分泌途径中的关键分子。基于这一发现,BioMarck开发了一种新型多肽BIO-11006,它在培养的人呼吸道上皮细胞和各种啮齿动物模型中抑制粘液高分泌和炎性介质的释放。BIO-11006是一种粘液分泌和炎症的双重功能抑制剂,是潜在治疗包括慢性阻塞性肺疾病在内的各种肺部疾病的理想药物。在SBIR赠款的资助下,BioMarck继续这一项目的工作,最近在活跃的IND下,成功地完成了一项为期21天的概念验证第2A期临床研究,使用其先导化合物BIO-11006对172名患有慢性支气管炎的慢性阻塞性肺疾病患者进行了研究。这一申请将使BioMarck能够利用BIO-11006对300名慢性支气管炎慢性阻塞性肺疾病患者进行为期90天的多中心、双盲、剂量选择临床研究。拟议项目的成功完成将使BioMarck能够为最终的3期临床研究选择剂量水平。在世界范围内,慢性阻塞性肺病的社会和经济负担是巨大的。慢性阻塞性肺疾病,作为第三个。主要死因,在全世界造成500多万人死亡。尽管目前市场上有超过25种不同的药物可供选择,但患者和护理提供者迫切需要有效的药物来治疗COPD。BIO-11006通过减少多余的粘液和呼吸道炎症,有可能成为有效治疗这类患者的一流药物。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Inhibition of myristoylated alanine-rich C kinase substrate (MARCKS) protein inhibits ozone-induced airway neutrophilia and inflammation.
- DOI:10.3109/01902140903131200
- 发表时间:2010-03
- 期刊:
- 影响因子:1.7
- 作者:Damera G;Jester WF;Jiang M;Zhao H;Fogle HW;Mittelman M;Haczku A;Murphy E;Parikh I;Panettieri RA Jr
- 通讯作者:Panettieri RA Jr
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Indu Parikh其他文献
Indu Parikh的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Indu Parikh', 18)}}的其他基金
Clinical Development a Therapeutic Agent for COPD
慢性阻塞性肺病治疗剂的临床开发
- 批准号:
7195094 - 财政年份:2003
- 资助金额:
$ 100万 - 项目类别:
Clinical Development a Therapeutic Agent for COPD
慢性阻塞性肺病治疗剂的临床开发
- 批准号:
8051355 - 财政年份:2003
- 资助金额:
$ 100万 - 项目类别:
Clinical Development of a Therapeutic Agent for COPD
慢性阻塞性肺病治疗剂的临床开发
- 批准号:
8708186 - 财政年份:2003
- 资助金额:
$ 100万 - 项目类别:
Preclinical Development of a Therapeutic Agent for COPD
慢性阻塞性肺病治疗药物的临床前开发
- 批准号:
6833123 - 财政年份:2003
- 资助金额:
$ 100万 - 项目类别:
Clinical Development a Therapeutic Agent for COPD
慢性阻塞性肺病治疗剂的临床开发
- 批准号:
7621039 - 财政年份:2003
- 资助金额:
$ 100万 - 项目类别:
Clinical Development of a Therapeutic Agent for COPD
慢性阻塞性肺病治疗剂的临床开发
- 批准号:
8495831 - 财政年份:2003
- 资助金额:
$ 100万 - 项目类别:
Inhibition of Mucin Secretion in Murine Model of Asthma
哮喘小鼠模型中粘蛋白分泌的抑制
- 批准号:
6646157 - 财政年份:2003
- 资助金额:
$ 100万 - 项目类别:
Clinical Development a Therapeutic Agent for COPD
慢性阻塞性肺病治疗剂的临床开发
- 批准号:
7053538 - 财政年份:2003
- 资助金额:
$ 100万 - 项目类别:
Preclinical Development of a Therapeutic Agent for COPD
慢性阻塞性肺病治疗药物的临床前开发
- 批准号:
6944906 - 财政年份:2003
- 资助金额:
$ 100万 - 项目类别:
MICRODROPLET-BASED SUSTAINED DELIVERY OF AZIDOTHYMIDINE
基于微滴的叠氮胸苷持续递送
- 批准号:
3489561 - 财政年份:1992
- 资助金额:
$ 100万 - 项目类别:
相似海外基金
Simulating Urban Air Pollution In The Lab
在实验室模拟城市空气污染
- 批准号:
MR/Y020014/1 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Fellowship
Suppression of air pollution via aerosol mediated removal of peroxy radicals
通过气溶胶介导去除过氧自由基抑制空气污染
- 批准号:
NE/Y000226/1 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Research Grant
Geographic and Sociodemographic Variability in Air Pollution Exposure
空气污染暴露的地理和社会人口变化
- 批准号:
2342266 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Standard Grant
Air-pollution Innovation in Regional-forecasts utilising operational Satellite Applications and Technologies (AIRSAT)
利用卫星应用和技术(AIRSAT)进行区域预测的空气污染创新
- 批准号:
NE/Y005147/1 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Research Grant
Health effects of low-concentration, non-urban air pollution: health impacts of ship emission controls
低浓度非城市空气污染对健康的影响:船舶排放控制对健康的影响
- 批准号:
23H03158 - 财政年份:2023
- 资助金额:
$ 100万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Air pollution and Asthma in Canada: Projections of burden and the value of climate adaptation strategies
加拿大的空气污染和哮喘:负担预测和气候适应战略的价值
- 批准号:
485322 - 财政年份:2023
- 资助金额:
$ 100万 - 项目类别:
Operating Grants
The Political Economy of Vulnerability to Air Pollution in Kathmandu Valley, Nepal
尼泊尔加德满都谷地空气污染脆弱性的政治经济学
- 批准号:
2884672 - 财政年份:2023
- 资助金额:
$ 100万 - 项目类别:
Studentship
Improving our understanding of the atmospheric sulfur cycle and its impact on air pollution and climate
提高我们对大气硫循环及其对空气污染和气候影响的了解
- 批准号:
2885122 - 财政年份:2023
- 资助金额:
$ 100万 - 项目类别:
Studentship
Impacts of Air Pollution from Ultrafine Tire-Wear Particles on Cardiorespiratory Health
超细轮胎磨损颗粒造成的空气污染对心肺健康的影响
- 批准号:
2899750 - 财政年份:2023
- 资助金额:
$ 100万 - 项目类别:
Studentship
The Renin-Angiotensin System in Air Pollution-Mediated Exacerbation of Obesity.
空气污染介导的肥胖加剧中的肾素-血管紧张素系统。
- 批准号:
10654124 - 财政年份:2023
- 资助金额:
$ 100万 - 项目类别: